It's been quite the run for the Gophers men's basketball team. After an 0-6 start to Big Ten play, the Gophers have now ...
Leerink Partners analyst Marc Goodman maintained a Buy rating on Johnson & Johnson (JNJ – Research Report) yesterday and set a price target ...
FOX Sports' Keyshawn Johnson had high praise for Commanders rookie QB Jayden Daniels on his "All Facts No Brakes" podcast.
Early in Thursday's loss to the Toronto Raptors, Hawks star forward Jalen Johnson left the game early with a shoulder injury ...
Analyst Tim Anderson of Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research Report), reducing the ...
Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.
Cam Johnson's Nets future remains unclear as he remains sidelined by an ankle injury with the trade deadline approaching.
Johnson & Johnson (JNJ) beat on fourth quarter and full-year 2024 results, but its stock traded down on Wednesday morning to about $143 per share. Several negative impacts were highlighted in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback